Seeking Alpha
06 Jul 2026, 07:02 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
Syntara reported preliminary Phase II results for SNT-4728 in patients with isolated REM Sleep Behavior Disorder (iRBD). — Clinical trial data for a lead candidate is a primary catalyst for biotech valuation and risk appetite.
+0.60Which stocks this story touches
The company is reporting preliminary Phase II results for a drug candidate, which typically represents progress in a clinical pipeline.
Continue reading
6 related stories
Top 1 mover · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
10h ago
